STOCK TITAN

enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

enVVeno Medical (NVNO) will present three-year VenoValve results from its U.S. pivotal SAVVE study at the 53rd Annual VEITH Symposium. Patients with severe chronic venous insufficiency showed sustained, statistically significant improvements in disease severity, leg pain and quality of life. The revised Venous Clinical Severity Score (rVCSS) improved by an average of 5.8 points from baseline to 36 months. Disease-specific quality-of-life and symptom scores improved by an average of 18 and 19 points, respectively.

The presentation will also highlight enVVe, a replacement venous valve designed for catheter delivery rather than open surgery. The FDA authorized the TAVVE pivotal study in April 2026 under an Investigational Device Exemption. enVVeno expects to enroll the first patient by year-end 2026 and plans to proceed to Part 2 after FDA review.

Loading...
Loading translation...
6 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointDisease severity improved by an average of 5.8 points on rVCSS from baseline to 36 months
  • Moderate pointFDA authorization under an Investigational Device Exemption for the enVVe pivotal study was granted in April 2026
  • Minor pointLeg pain showed statistically significant improvement sustained through three years
  • Minor pointVenous disease-specific quality of life improved by an average of 18 points
  • Minor pointVenous disease-specific symptoms improved by an average of 19 points
  • Minor point. Forward-looking: it has not happened yet and may not happen.First TAVVE patient enrollment remains on track for year-end 2026, enVVeno Medical said

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.TAVVE Part 2 is planned to follow FDA review after initial safety monitoring in Part 1

News Explained

The TAVVE study is staged: Part 1 will include up to 10 patients initially monitored for safety, and the company plans Part 2 following FDA review, where regurgitant flow volume and rVCSS will be evaluated.

Key Figures

Average rVCSS improvement: 5.8 points Average VEINES-QOL improvement: 18 points Average VEINES-Sym improvement: 19 points +4 more
Average rVCSS improvement
5.8 points
SAVVE; baseline to 36 months
Average VEINES-QOL improvement
18 points
SAVVE; venous disease-specific quality of life
Average VEINES-Sym improvement
19 points
SAVVE; venous disease-specific symptoms
SAVVE study size
75 patients
Severe chronic venous insufficiency due to deep venous reflux
TAVVE Part 1 enrollment
Up to 10 patients
Initial safety monitoring
FDA IDE authorization
April 2026
TAVVE pivotal study
First TAVVE patient enrollment
By year-end 2026
Company says it remains on track

Key Terms

chronic venous insufficiency, investigational device exemption, transcatheter
3 terms
chronic venous insufficiency medical
"patients with severe chronic venous insufficiency (CVI)"
A long-term condition in which the one-way valves in leg veins do not work properly, causing blood to pool, swelling, pain, skin changes or ulcers; think of it as a plumbing problem where backflow wears out pipes and fixtures. Investors care because it is a common, chronic market with ongoing demand for treatments, devices and wound-care products, and outcomes depend on clinical data, regulatory approvals and reimbursement decisions that affect revenue streams.
investigational device exemption regulatory
"received FDA Investigational Device Exemption (IDE) authorization"
An investigational device exemption (IDE) is a regulatory permission that allows a medical device maker to test an unapproved device in people so the device’s safety and effectiveness can be studied. For investors, an IDE matters because it marks a formal step toward regulatory approval—like getting a temporary test-drive permit—and influences clinical cost, timelines, and the likelihood a device will reach the market and generate revenue.
transcatheter medical
"the Company's next-generation, non-surgical transcatheter replacement venous valve"
Transcatheter describes medical procedures or devices delivered through a thin, flexible tube (catheter) that is threaded through blood vessels or small body openings to reach the heart or other organs without open surgery. It matters to investors because transcatheter approaches enable faster recovery, shorter hospital stays and larger patient pools for treatments that once required major operations, which can expand market demand and affect device and hospital revenues.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

IRVINE, CA / ACCESS Newswire / November 20, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, will present three-year data from SAVVE, the U.S. pivotal study of the VenoValve® today at the 53rd Annual Vascular and Endovascular Issues, Techniques and Horizons (VEITH) Symposium in New York City. The data, which will be presented by Dr. David Dexter of Sentara Vascular Specialists, shows sustained, statistically significant improvements in the revised Venous Clinical Severity Score (rVCSS), leg pain and quality-of-life measures in patients with severe chronic venous insufficiency (CVI). The presentation will also highlight enVVe®, the Company's next-generation, non-surgical transcatheter replacement venous valve.

Among the data being presented at VEITH are:

  • 5.8-point average improvement in disease severity, as measured by rVCSS, from baseline to 36 months.
  • 18-point and 19-point average improvements in venous disease-specific quality of life (VEINES-QOL) and symptoms (VEINES-Sym), respectively.

The rVCSS is a clinically validated scoring system used to track the progression or regression of venous diseases, and a 5.8-point improvement represents a real difference in the daily lives of these patients. Improvement was observed as early as three months following implantation and was sustained through 36 months.

"Patients improved significantly after receiving the VenoValve, and this three-year data shows that those benefits have been sustained," said Robert Berman, Chief Executive Officer of enVVeno Medical. "Demonstrating the long-term viability of our replacement venous valve technology is critically important as we advance enVVe."

enVVe, the Company's next-generation, non-surgical replacement venous valve, builds on the clinical experience gained with VenoValve. Unlike VenoValve, which requires an open surgical procedure and an overnight hospital stay, enVVe is designed to be implanted in a less invasive procedure performed under light sedation, with patients expected to go home the same day.

enVVe will be evaluated in TAVVE (TrAnscatheter Venous Valve Endoprosthesis), a prospective, multicenter pivotal study that received FDA Investigational Device Exemption (IDE) authorization in April 2026. Part 1 of the TAVVE pivotal study will consist of up to 10 patients who will initially be monitored for safety. Following FDA review, the Company plans to proceed to Part 2 of the TAVVE pivotal study, which will evaluate regurgitant flow volume and rVCSS, along with other secondary endpoints. The Company remains on track to enroll the first patient in TAVVE by year-end 2026.

About the enVVe System

The investigational enVVe System is a transcatheter-delivered replacement venous valve designed to restore one-way blood flow in the deep veins of patients with chronic venous insufficiency. An estimated 3 million people in the U.S. suffer from severe deep venous insufficiency, and it remains one of the largest unmet needs in vascular medicine. As venous valves fail, patients often experience chronic pain, swelling, skin changes, recurrent venous leg ulcers and declining quality of life.

Despite the significant burden of deep venous insufficiency, treatment options remain limited and are primarily focused on managing symptoms through compression therapy and wound care rather than addressing the underlying cause: dysfunctional venous valves. The enVVe System is being developed to address this critical treatment gap by helping restore proper directional blood flow to the deep venous system.

About the SAVVE Study

The SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) study is a prospective, single-arm, multicenter U.S. pivotal clinical study evaluating VenoValve in 75 patients with severe chronic venous insufficiency due to deep venous reflux across 21 U.S. clinical centers. The study includes patients with CEAP clinical classifications C4b through C6 and evaluates changes in disease severity, pain, quality of life, symptoms, venous ulcer area and device patency, with follow-up extending to five years.

About enVVeno Medical Corporation

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

INVESTOR CONTACT:
JTC Team, LLC
Jenene Thomas
NVNO@jtcir.com
(908) 824-0775

SOURCE: enVVeno Medical Corporation



View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did enVVeno Medical's three-year VenoValve study show?

In SAVVE, the revised Venous Clinical Severity Score improved by an average of 5.8 points from baseline to 36 months. Improvement was observed as early as three months after implantation. Disease-specific quality-of-life and symptom scores improved by an average of 18 and 19 points, respectively, and leg pain also showed sustained, statistically significant improvement.

What will enVVeno Medical evaluate in the TAVVE study of enVVe?

TAVVE will start with safety monitoring in up to 10 patients. After FDA review, enVVeno Medical plans to proceed to Part 2, which will measure the volume of backward blood flow and the revised Venous Clinical Severity Score, along with other secondary measures.

Keep reading